NCCN
NCCN Calls ctDNA Emerging Colon Cancer Prognostic Marker, Does Not Back Use Outside Clinical Trials
The panel noted limited data on whether recurrence risk scores from ctDNA testing or multigene assays predict chemotherapy benefit among colon cancer patients.
Pre-Surgery Immunotherapy, This Time With an Anti-LAG3/PD-1 Duo, Wows Again at ESMO
After the robust activity seen in 2023 with Opdivo-Yervoy in colorectal cancer, Opdivo-relatlimab garnered attention this year with a 100 percent response rate.
EMA's CHMP Recommends Gilead Sciences' Trodelvy for HR-Positive, HER2-Negative Breast Cancer
The European Commission is expected to decide whether to approve Trodelvy for advanced, pretreated HR-positive, HER2-negative breast cancer patients later this year.
NCCN Adds Krazati, Lumakras to Updated Pancreatic Cancer Guidelines
The group recommends both drugs, currently approved for lung cancer, for certain KRAS G12C-mutant pancreatic cancer patients based on encouraging data from trials.
An analysis of whole-exome sequencing results presented at AACR suggests many people with hereditary cancer risk variants don't fall under current NCCN guidelines.